In the ME/CFS Lines consortium, several national and international research partners develop biomedical research on ME/CFS. This consortium uses data and biomaterials collected since 2006 in the Lifelines population cohort, which includes over 167,000 participants.
Questionnaires and diagnostic tests are used to identify ME/CFS patients within Lifelines. Biomaterials are used to map genetics, microbiome, antibody repertoire, proteome and metabolome in ME/CFS patients and matched controls.
The emphasis is on a multi-omics approach, for which biomaterials from before the onset of ME/CFS are also available. With these data, researchers within this consortium will search for new mechanisms that may explain the onset of ME/CFS, in order to achieve better diagnosis and treatment.
Timeline
DEC-2023 to JAN-2024
DSQ-2 to all adult participants
JAN-2024 to MAY-2024
Pre-selection of ME/CFS Lines cohort based on DSQ-2
JUN-2024 to DEC-2024
Collection of diagnostic data and biomaterials
2025
Analysis of biomaterials for mechanistic studies
Data and Biomaterials
- Cardiovascular function (ECG, blood pressure)
- Cognitive functioning
- Lung function (spirometry)
- Anthropometry
- Psychiatric interview
- Biomaterials (blood, urine, feces)
- Genetics
- Microbiome
- antibody repertoire (PhipSeq)
- Proteome (OLink)
- Metabolome
Funding opportunities
- ME/CFS Lines
- NMCB